Long-term follow-up of successful hepatitis C virus therapy: Waning immune responses and disappearance of liver disease are consistent with cure

Alimentary Pharmacology and Therapeutics

Volumn 41, Issue 6, 2015, Pages 532-543

  Hedenstierna, M ^a,b   Weiland, O ^a,b   Brass, A ^b   Bankwitz, D ^c   Behrendt, P ^c   Uhnoo, I ^d   Aleman, S ^a   Cardell, K ^e   Fryden, A ^e   Norkrans, G ^f   Eilard, A ^f   Glaumann, H ^a   Pietschmann, T ^c   Sallberg M ^b   Brenndorfer E D ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c INSTITUTE OF INFECTION IMMUNOLOGY   (Germany)

^d UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^e LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^f SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA2B INTERFERON; ASPARTATE AMINOTRANSFERASE; GAMMA INTERFERON; HEPATITIS C ANTIBODY; NEUTRALIZING ANTIBODY; NONSTRUCTURAL PROTEIN 3; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA; ANTIVIRUS AGENT; BIOLOGICAL MARKER;

ADULT; ANTIBODY TITER; ARTICLE; ASPARTATE AMINOTRANSFERASE TO PLATELET RATIO INDEX; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; FOLLOW UP; GOTEBORG UNIVERSITY CIRRHOSIS INDEX; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS SUBTYPE 1A; HEPATITIS C VIRUS SUBTYPE 1B; HEPATITIS C VIRUS SUBTYPE 3A; HEPATOBILIARY PARAMETERS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; INTERFERON PRODUCTION; LIVER DISEASE; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PERIPHERAL BLOOD MONONUCLEAR CELL; SUSTAINED VIRAL RESPONSE; VIRAL CLEARANCE; VIRUS NEUTRALIZATION; BIOPSY; BLOOD; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; IMMUNOLOGY; METABOLISM; MONONUCLEAR CELL; T LYMPHOCYTE; VIROLOGY;

ADULT; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; BIOPSY; FEMALE; FOLLOW-UP STUDIES; HEPACIVIRUS; HEPATITIS C ANTIBODIES; HEPATITIS C, CHRONIC; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; RNA, VIRAL; T-LYMPHOCYTES;

EID: 84922787541     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13096     Document Type: Article

References (35)

1. Thomas DL,. Global control of hepatitis C: where challenge meets opportunity. Nat Med 2013; 19: 850-8.
2. Bode JG, Brenndorfer ED, Haussinger D,. Hepatitis C virus (HCV) employs multiple strategies to subvert the host innate antiviral response. Biol Chem 2008; 389: 1283-98.
3. Brenndorfer ED, Sallberg M,. Hepatitis C virus-mediated modulation of cellular immunity. Arch Immunol Ther Exp (Warsz) 2012; 60: 315-29.
4. Cramp ME, Rossol S, Chokshi S, Carucci P, Williams R, Naoumov NV,. Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C. Gastroenterology 2000; 118: 346-55.
5. Diepolder HM, Zachoval R, Hoffmann RM, et al,. Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection. Lancet 1995; 346: 1006-7.
6. Hoofnagle JH, Seeff LB,. Peginterferon and ribavirin for chronic hepatitis C. N Engl J Med 2006; 355: 2444-51.
7. Liang TJ, Ghany MG,. Current and future therapies for hepatitis C virus infection. N Engl J Med 2013; 368: 1907-17.
8. Castillo I, Rodriguez-Inigo E, Lopez-Alcorocho JM, Pardo M, Bartolome J, Carreno V,. Hepatitis C virus replicates in the liver of patients who have a sustained response to antiviral treatment. Clin Infect Dis 2006; 43: 1277-83.
9. Pham TN, MacParland SA, Mulrooney PM, Cooksley H, Naoumov NV, Michalak TI,. Hepatitis C virus persistence after spontaneous or treatment-induced resolution of hepatitis C. J Virol 2004; 78: 5867-74.
10. Radkowski M, Gallegos-Orozco JF, Jablonska J, et al,. Persistence of hepatitis C virus in patients successfully treated for chronic hepatitis C. Hepatology 2005; 41: 106-14.
11. Veerapu NS, Raghuraman S, Liang TJ, Heller T, Rehermann B,. Sporadic reappearance of minute amounts of hepatitis C virus RNA after successful therapy stimulates cellular immune responses. Gastroenterology 2011; 140: 676-85 e1.
12. Castillo I, Pardo M, Bartolome J, et al,. Occult hepatitis C virus infection in patients in whom the etiology of persistently abnormal results of liver-function tests is unknown. J Infect Dis 2004; 189: 7-14.
13. Veerapu NS, Park SH, Tully DC, Allen TM, Rehermann B,. Trace amounts of sporadically reappearing HCV RNA can cause infection. J Clin Invest 2014; 124: 3469-78.
14. Fujii H, Itoh Y, Ohnishi N, et al,. Relapse of hepatitis C in a pegylated-interferon-alpha-2b plus ribavirin-treated sustained virological responder. Hepatol Res 2010; 40: 654-60.
15. Lee WM, Polson JE, Carney DS, Sahin B, Gale M Jr,. Reemergence of hepatitis C virus after 8.5 years in a patient with hypogammaglobulinemia: evidence for an occult viral reservoir. J Infect Dis 2005; 192: 1088-92.
16. Lin A, Thadareddy A, Goldstein MJ, Lake-Bakaar G,. Immune suppression leading to hepatitis C virus re-emergence after sustained virological response. J Med Virol 2008; 80: 1720-2.
17. Westin J, Ydreborg M, Islam S, et al,. A non-invasive fibrosis score predicts treatment outcome in chronic hepatitis C virus infection. Scand J Gastroenterol 2008; 43: 73-80.
18. Wai CT, Greenson JK, Fontana RJ, et al,. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518-26.
19. Bedossa P, Poynard T,. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24: 289-93.
20. Castera L, Forns X, Alberti A,. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol 2008; 48: 835-47.
21. Jensen TB, Gottwein JM, Scheel TK, Hoegh AM, Eugen-Olsen J, Bukh J,. Highly efficient JFH1-based cell-culture system for hepatitis C virus genotype 5a: failure of homologous neutralizing-antibody treatment to control infection. J Infect Dis 2008; 198: 1756-65.
22. Haid S, Novodomska A, Gentzsch J, et al,. A plant-derived flavonoid inhibits entry of all HCV genotypes into human hepatocytes. Gastroenterology 2012; 143: 213-22 e5.
23. Morishima C, Morgan TR, Everhart JE, et al,. Interpretation of positive transcription-mediated amplification test results from polymerase chain reaction-negative samples obtained after treatment of chronic hepatitis C. Hepatology 2008; 48: 1412-9.
24. Hoare M, Gelson WT, Rushbrook SM, et al,. Histological changes in HCV antibody-positive, HCV RNA-negative subjects suggest persistent virus infection. Hepatology 2008; 48: 1737-45.
25. George SL, Bacon BR, Brunt EM, Mihindukulasuriya KL, Hoffmann J, Di Bisceglie AM,. Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients. Hepatology 2009; 49: 729-38.
26. Castillo I, Rodriguez-Inigo E, Bartolome J, et al,. Hepatitis C virus replicates in peripheral blood mononuclear cells of patients with occult hepatitis C virus infection. Gut 2005; 54: 682-5.
27. Pawelczyk A, Kubisa N, Jablonska J, et al,. Detection of hepatitis C virus (HCV) negative strand RNA and NS3 protein in peripheral blood mononuclear cells (PBMC): CD3 +, CD14 + and CD19 +. Virol J 2013; 10: 346.
28. Fujiwara K, Allison RD, Wang RY, et al,. Investigation of residual hepatitis C virus in presumed recovered subjects. Hepatology 2013; 57: 483-91.
29. Natarajan V, Kottilil S, Hazen A, et al,. HCV in peripheral blood mononuclear cells are predominantly carried on the surface of cells in HIV/HCV co-infected individuals. J Med Virol 2010; 82: 2032-7.
30. Riva E, Maggi F, Abbruzzese F, et al,. Immune complexed (IC) hepatitis C virus (HCV) in chronically and acutely HCV-infected patients. Med Microbiol Immunol 2009; 198: 13-8.
31. Giannini EG, Basso M, Savarino V, Picciotto A,. Sustained virological response to pegylated interferon and ribavirin is maintained during long-term follow-up of chronic hepatitis C patients. Aliment Pharmacol Ther 2010; 31: 502-8.
32. Radkowski M, Horban A, Gallegos-Orozco JF, et al,. Evidence for viral persistence in patients who test positive for anti-hepatitis C virus antibodies and have normal alanine aminotransferase levels. J Infect Dis 2005; 191: 1730-3.
33. Carreno V, Pardo M, Lopez-Alcorocho JM, Rodriguez-Inigo E, Bartolome J, Castillo I,. Detection of hepatitis C virus (HCV) RNA in the liver of healthy, anti-HCV antibody-positive, serum HCV RNA-negative patients with normal alanine aminotransferase levels. J Infect Dis 2006; 194: 53-60.
34. Poynard T, Moussalli J, Munteanu M, et al,. Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C. J Hepatol 2013; 59: 675-83.
35. Martinez SM, Fernandez-Varo G, Gonzalez P, et al,. Assessment of liver fibrosis before and after antiviral therapy by different serum marker panels in patients with chronic hepatitis C. Aliment Pharmacol Ther 2011; 33: 138-48.